TAGRISSO AstraZeneca Pty Ltd
Product name
TAGRISSO
Sponsor
Accepted date
Oct-2023
Active ingredients
osimertinib mesilate
Proposed indication
TAGRISSO is indicated in combination for locally advanced or metastatic NSCLC whose tumours have activating EGFR mutations.
Application type
C (new indication)
Publication date
Oct-2023